Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

Status:

WITHDRAWN

Preventing Tolerance to Oxymetazoline in Allergic Rhinitis

Lead Sponsor:

Brian J Lipworth

Conditions:

Allergic Rhinitis

Tachyphylaxis

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The investigators wish to evaluate the effects of decongestants like oxymetazoline and the lessening of this effect with time called 'tolerance'. The investigators will demonstrate a reversal of this ...

Detailed Description

Allergic rhinitis (AR) affects upto 25% of the worldwide population and is associated with asthma, with Scotland having the highest prevalence in the world. Nasal blockage is the main symptom of aller...

Eligibility Criteria

Inclusion

Male of Female aged 18-65 years.
Persistent allergic rhinitis with or without asthma.
Atopy to atleast one allergen on SPT.
PNIF \< 120 L/min (best of 3) and reversibility with OXY \>20L/min.
Ability to give a written informed consent.
Ability and willingness to comply with the requirements of the protocol.

Exclusion

Recent respiratory tract/sinus infection within the last 2 months. .
Pregnancy, planned pregnancy or lactation.
Known or suspected hypersensitivity to any of the IMP's.
Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.
Nasal Polyposis grade 2+, Deviated nasal septum ≥ 50%
The use of oral corticosteroids within the last 3 months.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00846326

Last Update

October 25 2016

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee)

Dundee, United Kingdom, DD1 9SY